Navigation Links
Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
Date:5/15/2008

MELBOURNE, Australia, May 15 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) today announced that the abstract for its upcoming oral presentation on CYT997 at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be accessible to the public via ASCO's website (http://www.asco.org) from 9pm on Thursday 15 May (US EDT).

The oral presentation, entitled "Phase I evaluation of CYT997, a novel cytotoxic and vascular disrupting agent, in patients with advanced cancer" will be presented to the meeting by Dr Jason Lickliter, Clinical Study Chairman on 2 June 2008.

The meeting, to be held in Chicago, attracts more than 30,000 delegates from around the world.

About CYT997

CYT997 is a vascular disrupting agent (VDA) with a dual mechanism of action that shuts down established blood vessels supplying the tumor with nutrients and oxygen as well as being a general cytotoxic agent. The compound, which was discovered by Cytopia in 2003, can be delivered orally as well as intravenously and was the subject of a successful IND application to the US Food and Drug Administration in 2005. Phase I and Phase II clinical studies with CYT997 in different oncology settings are currently underway.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
9. Immunosyn Corporation Releases SF-1019 Study Results
10. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
11. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... Sept. 7, 2017 Caris Life Sciences, ... fulfilling the promise of precision medicine, today announced ... benefits of its molecular profiling approach in guiding ... genomic profiling plus (CGP+) with Caris Molecular Intelligence ... on a molecular level, leading to more therapeutic ...
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
Breaking Medicine Technology:
(Date:9/20/2017)... , ... September 20, 2017 , ... In just a ... Booster has already been receiving positive feedback from customers trying the product for the ... , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone from ...
(Date:9/20/2017)... ... 20, 2017 , ... Health & Safety Institute (HSI) is offering discounted pricing ... 40-Hour courses from now until November 30, 2017 to assist with the clean-up efforts ... to all businesses and government agencies – whether or not they will be directly ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. That’s ... and rolled up their sleeves to help with relief efforts. The team picked up ... of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms have ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a church ... “They Sang At Her Funeral” is the creation of published author, Annalise Harold, an ... and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often ...
(Date:9/19/2017)... Alabama (PRWEB) , ... September 19, 2017 , ... ... customer success story on St. Vincent’s Infusion Services called, “PAPA Healthcare helps fill ... St. Vincent’s Infusion Services enhanced service delivery and operations by leveraging PAPA Healthcare’s ...
Breaking Medicine News(10 mins):